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OBJECTIVE—Measurement of plasma C2 glucose enrichment
is cumbersome. Therefore, the plasma C5 glucose–to–
2H2O
rather than the plasma C5-to-C2 glucose ratio commonly has
been used to measure gluconeogenesis and glycogenolysis dur-
ing hyperinsulinemic-euglycemic clamps. The validity of this
approach is unknown.
RESEARCH DESIGN AND METHODS—Ten nondiabetic and
10 diabetic subjects ingested
2H2O the evening before study. The
following morning, insulin was infused at a rate of 0.6 mU  kg
1
 min
1 and glucose was clamped at 5.3 mmol/l for 5 h. Plasma
C5 glucose, C2 glucose, and
2H2O enrichments were measured
hourly from 2 h onward.
RESULTS—Plasma C2 glucose and plasma
2H2O enrichment
were equal in both groups before the clamp, resulting in equiv-
alent estimates of gluconeogenesis and glycogenolysis. In con-
trast, plasma C2 glucose and plasma C5 glucose enrichments fell
throughout the clamp, whereas plasma
2H2O enrichment re-
mained unchanged. Since the C5 glucose concentration and,
hence, the C5 glucose–to–
2H2O ratio is inﬂuenced by both
gluconeogenesis and glucose clearance, whereas the C5-to-C2
glucose ratio is only inﬂuenced by gluconeogenesis, the C5
glucose–to–
2H2O ratio overestimated (P  0.01) gluconeogenesis
during the clamp. This resulted in biologically implausible nega-
tive (i.e., calculated rates of gluconeogenesis exceeding total
endogenous glucose production) rates of glycogenolysis in both
the nondiabetic and diabetic subjects.
CONCLUSIONS—Plasma C5 glucose–to–
2H2O ratio does not
provide an accurate assessment of gluconeogenesis in nondia-
betic or diabetic subjects during a traditional (i.e., 2–3 h)
hyperinsulinemic-euglycemic clamp. The conclusions of studies
that have used this approach need to be reevaluated. Diabetes
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easurement of gluconeogenesis in humans is
difﬁcult. The deuterated water method is
widely used for this purpose (1–17). This
method relies on the fact that the ﬁfth carbon
of glucose is labeled during gluconeogenesis, whereas the
second carbon of glucose is labeled with deuterium during
equilibration of glucose-6-phosphate and fructose-6-
phoshate (1,2). Therefore, at steady state, the ratio of
plasma glucose with deuterium on the ﬁfth carbon (C5
glucose) to plasma glucose labeled on the second carbon
(C2 glucose) equals the percentage of plasma glucose
derived from gluconeogenesis (1,2). Measurement of C2
glucose enrichment is cumbersome. Since
2H2O and C2
glucose enrichments are equal at steady state, many
investigators have used the plasma C5 glucose–to–
2H2O
ratio to calculate gluconeogenesis after an overnight fast
(4–7,9–12,18). The C5 glucose–to–
2H2O ratio has also been
used to measure gluconeogenesis during glucose clamps
(4,6,7,11,12,18). However, the validity of this approach is
uncertain. We have reported that the rate of gluconeogen-
esis measured during the ﬁnal hour of a 3-h hyperinsuline-
mic-euglycemic clamp in lean nondiabetic subjects using
the C5-to-C2 glucose ratio correlated with that measured
in the same subjects using the C5 glucose–to–
2H2O ratio
(7). However, in those as well as other glucose clamp
experiments (4,6,7,11,12,18), gluconeogenesis calculated
using the C5 glucose–to–
2H2O ratio commonly exceeded
total endogenous glucose production. Since endogenous
glucose production equals the sum of glucose derived via
gluconeogenesis and glycogenolysis, this result was bio-
logically implausible.
Plasma C5 glucose concentrations are determined both
by the rate of appearance of C5 glucose into and the rate
of disappearance of C5 glucose from the plasma pool.
Therefore, the use of the C5 glucose–to–
2H2O ratio during
a clamp is only accurate when C5 glucose has achieved a
new steady state. Since hyperinsulinemic clamps typically
are relatively short (e.g., 2–3 h) and the glucose pool large,
we became concerned that plasma C5 glucose concentra-
tion was artiﬁcially elevated because the clearance was
not sufﬁciently rapid for C5 glucose concentration to have
reachieved a steady state at a lower concentration. If so,
thiswouldbeparticularlyproblematicwhentheC5glucose–
to–plasma
2H2O ratio was used to assess gluconeogenesis
in groups in whom insulin action, and therefore glucose
clearance, differed. The present experiments addressed
this question by measuring both plasma C5-to-C2 glucose
and the C5 glucose–to–
2H2O ratios in diabetic and non-
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1800 DIABETES, VOL. 57, JULY 2008diabetic subjects before and every hour from 2 h onward
during a 5-h hyperinsulinemic-euglycemic clamp.
RESEARCH DESIGN AND METHODS
Results for this report are derived from 10 nondiabetic subjects and 10
subjects with type 2 diabetes in whom sufﬁcient plasma was available to
permit measurement of C5 glucose, C2 glucose, and
2H2O enrichment at
hourly intervals during a prolonged hyperinsulinemic-euglycemic clamp.
Subject characteristics are given in supplemental Table 1 (available in an
online appendix at http://dx.doi.org/10.2337/db08-0195).
Details of the experimental design have been described in detail elsewhere
(19). Subjects were admitted to the Mayo Clinical Research Unit on the
evening before study and given a standard meal at 1700 h and 1.67 g
2H2O/kg
body water in divided doses at 1800, 2000, and 2200 h. Insulin was infused in
the diabetic subjects during the night to maintain glucose at 5.5 mmol/l. A
primed (fasting glucose divided by 5.5 mmol/l times 12 Ci), continuous (0.12
Ci/min) infusion of [3-
3H] glucose was started at 0700 h; infusions of insulin
(0.6 mU  kg
1  min
1), somatostatin (60 ng  kg
1  min
1), growth hormone
(3 ng  kg
1  min
1), and glucagon (0.65 ng  kg
1  min
1) were started at
1000 h (time 0 min). Glucose containing [3-
3H] glucose was infused in amounts
sufﬁcient to maintain euglycemia, as previously described (20). Plasma
glucose, insulin, [3-
3H] glucose speciﬁc activity, and enrichment of deuterium
on the 2nd and 5th carbons of plasma glucose were measured as previously
described (1,2,21).
Calculations. Rates are expressed in the ﬁgures and text as micromoles per
kilogram lean body mass per min. Rates of glucose appearance and disap-
pearance and endogenous glucose production were calculated using the
steady-state equations of Steele et al. (22) as previously described (19). Rates
of gluconeogenesis were calculated either by multiplying the plasma C5-to-C2
glucose ratio by endogenous glucose production or plasma C5 glucose–to–
2H2O ratio by the total rate of glucose appearance (2). Glycogenolysis was
calculated by subtracting the rate of gluconeogenesis from endogenous
glucose production. The results from the diabetic subjects have previously
been published, in part, elsewhere (19).
Statistical analysis. Data in the text and ﬁgures are expressed as means 
SEM. Student’s paired t test was used to determine whether rates calculated
using the plasma C5-to-C2 glucose ratio differed from those calculated using
the plasma C5 glucose/
2H2O ratio. A P value 0.05 was considered statistically
signiﬁcant.
RESULTS
Plasma glucose and insulin concentrations. Plasma
glucose concentrations (supplemental Fig. 1 in the nondi-
abetic and diabetic subjects averaged 5.31  0.16 and
5.41  0.10 mmol/l, respectively, before the clamp and did
not change during the clamp. Plasma insulin concentra-
tions in the nondiabetic and diabetic subjects averaged
31  4 and 178  41 pmol/l, respectively, before the clamp
and increased to 177  11 and 203  14 pmol/l during the
clamp.
Glucose infusion rate required to maintain euglyce-
mia and [3-
3H] glucose speciﬁc activity. The glucose
infusion rate required to maintain euglycemia increased in
both groups during the ﬁrst4ho ft h eclamp and plateaued
thereafter. The glucose infusion rate required to maintain
euglycemia during the ﬁnal hour of study was higher (P 
0.01) in the nondiabetic than in the diabetic subjects
(45.9  3.6 vs. 21.9  5.6 mol  kg
1  min
1, respec-
tively). Plasma [3-
3H] glucose speciﬁc activity remained
constant in both groups during the clamp, enabling accu-
rate measurement of glucose turnover (supplemental Fig.
2).
Glucose disappearance and endogenous glucose pro-
duction. Glucose disappearance increased in both groups
during the ﬁrst4ho ft h eclamp and remained unchanged
thereafter. In contrast, endogenous glucose production
was maximally suppressed in both groups within 3 hours.
Glucose disappearance during the ﬁnal hour of study was
higher (P  0.01) in the nondiabetic than diabetic subjects,
whereas endogenous glucose production did not differ
between groups (Fig. 1).
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FIG. 1. Glucose disappearance (A) and endogenous glucose production
(B). An insulin infusion was started at time zero.
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FIG. 2. Plasma enrichment of
2H2O, C2 glucose, and C5 glucose
observed in the nondiabetic and diabetic subjects. An insulin infusion
was started at time zero.
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2H2O, C2 glucose, and C5 glucose enrichment.
Plasma
2H2O and C2 glucose enrichment did not differ in
either the nondiabetic or diabetic subjects before the
clamp. Plasma
2H2O enrichment remained unchanged in
both groups during the clamp. In contrast, plasma C2
glucose and C5 glucose enrichment decreased (P  0.01)
in both groups during the clamp (Fig. 2).
Rates of gluconeogenesis and glycogenolysis calcu-
lated using the plasma C5 glucose–to–
2H2O and
plasma C5-to-C2 glucose ratios. Rates of gluconeogen-
esis and glycogenolysis measured before the clamp using
the plasma C5 glucose–to–
2H2O ratio did not differ from
those measured using the plasma C5-to-C2 glucose ratio in
either group. In contrast, rates of gluconeogenesis mea-
sured during the clamp using the plasma C5 glucose–to–
2H2O ratio were consistently greater (P  0.01) and
glycogenolysis consistently lower (P  0.01) than those
measured using the plasma C5-to-C2 glucose ratio in both
the nondiabetic and diabetic subjects, with the difference
most evident during the ﬁrst2ho ft h eclamp (Fig. 3).
Of note, rates of glycogenolysis calculated using the
plasma C5 glucose–to–
2H2O ratio were lower (P  0.05)
than zero at 120 min in the nondiabetic subjects, indicating
that calculated rates of gluconeogenesis exceeded endog-
enous glucose production. Rates of glycogenolysis calcu-
lated using the plasma C5 glucose–to–
2H2O ratio
converged toward zero thereafter. A similar pattern was
observed in the diabetic subjects, with rates of glyco-
genolysis calculated using the C5 glucose–to–
2H2O ratio
decreasing to less than zero at 120, 180, and 240 min and
converging toward zero thereafter.
Correlations. Rates of gluconeogenesis measured in the
nondiabetic subjects using the C5 glucose–to–
2H2O ratio
correlated (P  0.05) with rates measured using the
C5-to-C2 glucose ratio at all time points (Fig. 4). However,
the slopes did not equal one, and the y intercepts did not
equal zero. Rates of gluconeogenesis measured in the
diabetic subjects using the C5 glucose–to–
2H2O ratio were
not signiﬁcantly correlated with those measured using the
C5-to-C2 glucose ratio until 240 min, implying that the
contribution of gluconeogenesis relative to the contribu-
tion of glucose clearance to C5 glucose concentration
increased with time.
DISCUSSION
The present studies conﬁrm that the C5 glucose–to–
2H2O
and the C5-to-C2 glucose ratios provide equivalent esti-
mates of gluconeogenesis and glycogenolysis following an
overnight fast in both nondiabetic and diabetic subjects.
In contrast, use of the C5 glucose–to–
2H2O ratio during
an euglycemic-hyperinsulinemic clamp systematically
overestimates gluconeogenesis and underestimates
glycogenolysis.
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FIG. 3. Rates of gluconeogenesis and glycogenolysis measured in the nondiabetic (A and C) and diabetic (B and D) subjects using the plasma
C5-to-C2 glucose or plasma C5 glucose–to–
2H2O ratios. An insulin infusion was started at time zero.
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2H2O, the ﬁfth carbon of glucose is
labeled with deuterium during gluconeogenesis (1,2). The
second carbon of glucose is labeled with deuterium during
equilibration of glucose-6-phosphate and fructose-6 phos-
phate (1,2). At equilibrium, the enrichment of deuterium
on the second carbon of glucose equals that of plasma
water. Since plasma glucose derived from either glucone-
ogenesis or glycogenolysis passes though the glucose-6-
phosphate pool, at steady state either the C5 glucose–to–
2H2O or the C5-to-C2 glucose ratio equals the proportion of
plasma glucose derived from gluconeogenesis (1,2). The
situation changes during a hyperinsulinemic-euglycemic
clamp, when the rate of release of C5 glucose decreases as
a result of suppression of glucose production and the rate
of clearance of C5 glucose increases as a result of stimu-
lation of glucose uptake. As is evident from Fig. 2, C5
glucose enrichment fell throughout the5ho ft h estudy
in the diabetic subjects, indicating that equilibrium was
never reached. While C5 glucose enrichment also fell
during the clamp in the nondiabetic subjects, it ap-
peared to approach steady state during the ﬁnal hour of
the study. Therefore, plasma C5 glucose concentrations
during the ﬁrst portion of the clamp were higher than
those that would be present when a new steady state
was eventually achieved. In contrast, since C5 glucose
and C2 glucose are cleared in parallel, the C5-to-C2
glucose ratio is only inﬂuenced by the rates of release of
C5 glucose and C2 glucose, enabling assessment of
gluconeogenesis.
Since plasma C5 glucose enrichment is diluted by
both endogenously produced and exogenously infused
glucose, gluconeogenesis is calculated by multiplying
the C5 glucose–to–
2H2O ratio by total rate of glucose
appearance. Use of this approach resulted in rates of
gluconeogenesis that were not only greater than those
calculated using the C5-toC2 glucose ratio but that were
also greater than endogenous glucose production. This
yielded biologically implausible (i.e., negative) rates of
glycogenolysis. A similar pattern has been observed in
previous studies that have used the C5 glucose–to–
2H2O
ratio to calculate gluconeogenesis during a hyperinsu-
linemic clamp (4,6,7,11,12,18).
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FIG. 4. Correlation between the rates of gluconeogenesis in nondiabetic (A) and diabetic (B) subjects, measured using the C5 glucose–to–
2H2O
ratio and the C5-to-C2 glucose ratio.
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take and re-release of glucose (i.e., plasma glucose to
hepatic glucose-6-phosphate to plasma glucose) will cause
labeling of second carbon of glucose (1,2). This will reduce
the C5-to-C2 glucose ratio and will cause an underestima-
tion of gluconeogenesis. Although limited hepatic glucose
uptake occurs in the presence of euglycemia (23,24), the
impact of such cycling on the C5-to-C2 glucose ratio
during a hyperinsulinemic-euglycemic clamp is not
known. There is no gold standard with which in vivo
measurements of gluconeogenesis can be compared. The
present data merely indicate that since both gluconeogen-
esis and glucose clearance rates inﬂuence the C5 glucose
concentration, clamps must be conducted for a sufﬁcient
duration for plasma C5 glucose enrichment to reachieve a
steady state; otherwise, use of the C5 glucose–to–
2H2O
ratio yields erroneous estimates of both gluconeogenesis
and glycogenolysis.
In summary, the present studies indicate that while use
of the C5 glucose–to–
2H2O and C5-to-C2 glucose ratios
provide a comparable estimate of gluconeogenesis after an
overnight fast, they do not do so during a traditional 2-h
hyperinsulinemic-euglycemic clamp. Use of the C5–to–
glucose/
2H2O ratio during a glucose clamp overestimates
gluconeogenesis and underestimates glycogenolysis. In
contrast, since the C5-to-C2 glucose ratio only is inﬂu-
enced by gluconeogenesis, estimates obtained using this
ratio will not be altered by changes in glucose clearance.
We therefore recommend using the C5-to-C2 glucose ratio
to assess gluconeogenesis during a hyperinsulinemic
clamp. We also recommend performing the clamp for a
sufﬁcient duration (e.g., at least 3 h) so that the effects of
insulin on gluconeogenesis have time to become readily
evident.
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